Coagulation Testing Market by Product (Consumables, Instruments), Test Type (Activated Partial Thromboplastin Time, Prothrombin Time, Thrombin Time), End-User - Global Forecast 2024-2030

Coagulation Testing Market by Product (Consumables, Instruments), Test Type (Activated Partial Thromboplastin Time, Prothrombin Time, Thrombin Time), End-User - Global Forecast 2024-2030

The Coagulation Testing Market size was estimated at USD 4.62 billion in 2023 and expected to reach USD 5.07 billion in 2024, at a CAGR 9.92% to reach USD 8.96 billion by 2030.

Coagulation testing encompasses a range of diagnostic procedures aimed at assessing the blood's ability to clot properly. These tests are critical in diagnosing and managing various conditions that affect the blood's clotting capability, such as hemophilia, thrombosis, and liver disease. They are also essential in monitoring patients on anticoagulation therapy to ensure safe and effective treatment outcomes. The rising prevalence of cardiovascular diseases and blood disorders has increased the adoption of coagulation testing. Additionally, the aging global population at higher risk of blood-related disorders also significantly raises the need for coagulation testing. However, the high cost of coagulation testing devices and stringent regulatory requirements for the new devices' approval delay product launches, affecting market dynamics. Despite these challenges, increasing investment in healthcare infrastructure in emerging economies provides a future growth prospect. Furthermore, ongoing research and development activities aiming to introduce innovative and efficient coagulation testing solutions are expected to offer new avenues for expansion.

Regional Insights

In the Americas, coagulation testing is getting highly adopted owing to the high prevalence of cardiovascular diseases and an increasing aging population, particularly in North America. The United States showcases higher adoption, supported by advanced healthcare infrastructure and favorable reimbursement policies. The EMEA region presents diverse scenarios in the coagulation testing market, with Europe having a high adoption rate. The growth in Europe is spurred by the increasing adoption of point-of-care (POC) testing devices for faster and more efficient diagnosis, alongside strong healthcare systems and a higher level of patient awareness. The Middle East and Africa are witnessing gradual growth, with initiatives by governments and NGOs to improve healthcare facilities. Asia-Pacific is projected to be the biggest market for coagulation testing, driven by rapidly developing healthcare infrastructure and a large patient pool. Countries inclduing China and India are at the forefront of the adoption of coagulation testing, with their growing middle-class populations and increased focus on healthcare reform. Furthermore, the expanding research and development activities in the region to develop affordable testing solutions are expected to boost the market in this region.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Coagulation Testing Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

Increasing prevalence of coagulation disorders worldwide
Government campaigns promoting awareness of life-threatening blood clots

Market Restraints

Lack of reimbursements for coagulation testing

Market Opportunities

Advancements in coagulation testing technologies
Emergence of coagulation testing for homecare

Market Challenges

Technical limitations and inaccuracies of coagulation testing

Market Segmentation Analysis

Product: Rising deployment of automated instruments to achieve efficiency and scalability in coagulation testing
End-User: Growing adoption of home coagulation testing kits to support remote patient monitoring

Market Disruption Analysis

Porter’s Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Coagulation Testing Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Coagulation Testing Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Roche Launches Three New Factor Xa Inhibitor Coagulation Tests to Meet Growing Patient Need

Roche has introduced three new coagulation tests for the oral Factor Xa inhibitors apixaban, edoxaban, and rivaroxaban, available in countries recognizing the CE mark. Roche aims to enhance lab efficiency with their tests' compatibility with cobas t analysers and innovative Anti-Xa cassette technology, which standardizes the testing process and minimizes user intervention, contamination, and evaporation risks, thus facilitating a streamlined and more effective use of reagents and potentially improving patient outcomes.

HORIBA UK to Introduce New Fully Automated Haemostasis Analysers at IBMS Congress 2023

HORIBA has announced the expansion of its coagulation testing capabilities in the UK with the introduction of its cutting-edge, fully automated haemostasis analysers, the high-throughput Yumizen G1500h/G1550h and the compact Yumizen G800h/G850h models. These advanced systems are engineered to elevate precision by efficiently pinpointing and analyzing HIL interferences (haemolysis, icterus, and lipemia) in each coagulation test, alongside automatically assessing the primary tubes for adequacy of fill levels.

Diagnostica Stago Nabs FDA 510(k) Clearance for Coagulation Analyzers

Diagnostica Stago has achieved a significant milestone with the US Food and Drug Administration's 510(k) clearance for its latest Max Generation analyzers, the STA R Max3 and STA Compact Max3, designed to improve the diagnosis and monitoring of coagulation disorders and anticoagulant therapy. Engineered with cutting-edge features, these fully automated analyzers provide comprehensive testing capabilities such as clot-based, immunoturbidimetric, and colorimetric assessments.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Coagulation Testing Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Coagulation Testing Market, highlighting leading vendors and their innovative profiles. These include A&T Corporation, Abbott Laboratories, Advin Health Care, Becton, Dickinson and Company, Beijing Succeeder Technology Inc., Bio Group Medical System SRL, Bio-Rad Laboratories, Inc., Coagulation Sciences LLC, Danaher Corporation, Drucker Diagnostics, LLC, F. Hoffmann-La Roche Ltd, Genrui Biotech Inc., Helena Laboratories Corporation, HORIBA, Ltd., Maccura Biotechnology Co., Ltd., Medtronic PLC, Mindray Bio-Medical Electronics Co., Ltd., Sekisui Chemical Co., Ltd., Shenzhen Micropoint Biotechnologies Co., Ltd., Siemens Healthineers AG, Stago Group, Sysmex Corporation, Thermo Fisher Scientific Inc., Trivitron Healthcare, and Tulip Diagnostics (P) Ltd.

Market Segmentation & Coverage

This research report categorizes the Coagulation Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
Consumables
Instruments
Test Type
Activated Partial Thromboplastin Time
Prothrombin Time
Thrombin Time
End-User
Clinical Laboratories
Home Testing
Hospitals
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

Please Note: PDF & Excel + Online Access - 1 Year